The company operates two business lines: Drug Discovery and Drug Discovery Support. For the nine months ended Q3, revenue from Drug Discovery Support grew 37.8% year-over-year, while the Drug Discovery segment saw an expanded operating loss due to increased clinical development expenses. Clinical development costs for in-house pipelines (docirbrutinib\/sofnobrutinib\/monzosertib) rose. Upcoming data presentations at ASH2026 and progress such as ODD designations are notable. Financially, cash increased but liabilities rose, resulting in negative net assets.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4572","jir_company_name":"Carna Biosciences, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4572-20261106-02.pdf","jir_short_summary":"The company operates two business lines: Drug Discovery and Drug Discovery Support. For the nine months ended Q3, revenue from Drug Discovery Support grew 37.8% year-over-year, while the Drug Discovery segment saw an expanded operating loss due to increased clinical development expenses. Clinical development costs for in-house pipelines (docirbrutinib\/sofnobrutinib\/monzosertib) rose. Upcoming data presentations at ASH2026 and progress such as ODD designations are notable. Financially, cash increased but liabilities rose, resulting in negative net assets.","jir_summary":"### Business Portfolio and Performance Trends\nCarna Biosciences, Inc. operates two segments: Drug Discovery and Drug Discovery Support. For the cumulative Q3 of FY2026, Drug Discovery Support expanded significantly, with revenue of 573 million yen, an increase of 178 million yen and +45.1% year-over-year. Conversely, the Drug Discovery segment was burdened by increased clinical development costs, widening the operating loss. Overall operating loss amounted to 1,532 million yen (Q3 actuals), reflecting delays and increased expenses versus the full-year plan. The company is advancing clinical trials for its in-house pipeline\u2014docirbrutinib, sofnobrutinib, and monzosertib. Data presentations at ASH2026 are planned, and regulatory progress such as ODD designation could act as a tailwind.\n\n### Outlook and Impact for Investors\nBased on the cumulative Q3 results, Drug Discovery Support is expected to continue growing, while Drug Discovery will require continued investment in clinical development. In 2026, accelerating pipeline clinical development and securing external partnerships will be important. Data disclosures at ASH2026 and progress on ODD designations may expand opportunities for future milestone revenues and licensing-out. On funding, the company has executed financing such as issuance of bonds with warrants to secure a buffer for working capital and R&D expenses.","jir_financial_highlights":"Drug Discovery Support Revenue: 573 (Year-over-Year +178 \/ +45.1%)\nDrug Discovery Support Operating Loss: -82 (Year-over-Year +146 (impact of potential return to profitability unknown))\nDrug Discovery Operating Loss: -1,488 (Year-over-Year -127)\nResearch and Development Expenses: 1,461 (Year-over-Year +112)\nCash and Deposits: 1,241 (+65)","jir_category":"","jir_hashtags":"#CarnaBiosciences, #Earnings, #ClinicalDevelopment, #DrugDiscoveryPipeline","jir_key_figures":"Drug Discovery Support Revenue: 573 million yen (Year-over-Year +178 \/ +45.1%)\nDrug Discovery Support Operating Loss: -82 million yen\nDrug Discovery Operating Loss: -1,488 million yen\nResearch and Development Expenses: 1,461 million yen (Year-over-Year +112)\nCash and Deposits: 1,241 million yen (vs. prior +65)","jir_meta_title":"Carna Biosciences, Inc. FY2026 Q3 Results | Drug Discovery Support Grows, Drug Discovery Sees Wider Loss on Clinical Spend","jir_meta_description":"Summary of Carna Biosciences, Inc.'s FY2026 Q3 results. Drug Discovery Support revenue 573 million yen (+45.1% YoY). Drug Discovery incurred wider operating losses due to increased clinical development expenses. Key updates on docirbrutinib, sofnobrutinib, and monzosertib clinical progress and planned ASH2026 data releases.","jir_og_title":"Carna Biosciences, Inc. | Key Points from FY2026 Q3 Results and Pipeline Progress","jir_og_description":"Drug Discovery Support posted strong revenue growth while Drug Discovery saw losses widen due to higher clinical costs. Summary of the development status of three pipeline candidates with planned ASH2026 data releases.","jir_og_image_url":"","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Drug Discovery Support Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024Q3\\\",\\\"2025Q3\\\",\\\"2026Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Drug Discovery Support Revenue\\\",\\\"data\\\":[487,395,573]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Loss Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2024Q3\\\",\\\"2025Q3\\\",\\\"2026Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Drug Discovery Support Operating Loss\\\",\\\"data\\\":[-63,82,-82]},{\\\"label\\\":\\\"Drug Discovery Operating Loss\\\",\\\"data\\\":[-1488,-1615,-1488]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Regional Revenue Composition (Drug Discovery Support)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic\\\",\\\"Europe\\\",\\\"North America\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Drug Discovery Support Revenue\\\",\\\"data\\\":[395,0,0,0]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"R&D Expense Ratio\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 Q3\\\",\\\"2026 Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[1349,1461]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"table\", \"jir_chart_title\": \"Financial Metrics Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"table\\\",\\\"data\\\":[{\\\"indicator\\\":\\\"Full-Year Plan\\\" ,\\\"value\\\":\\\"Unknown\\\"},{\\\"indicator\\\":\\\"Actual\\\",\\\"value\\\":\\\"Unknown\\\"}]}\"}]","ir_related_company":59427,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-143730","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n